CGT Global, a US-based cell collection and expansion company, and Cellex Cell Professionals, a German cell therapy manufacturer, have partnered to improve scalability and patient access to cell and gene therapies (CGT). This collaboration leverages CGT Global’s US clinic and laboratory network and Cellex’s expertise in cell product manufacturing, particularly CAR-T therapies. The partnership aims to address the growing global demand for CGT while reducing costs and improving treatment accessibility.
This partnership is vital due to the increasing need for CGT manufacturing capabilities to support the growing number of therapies entering clinical trials and reaching commercialization. The combined expertise and resources of these two companies create a more efficient pathway from development to patient delivery, potentially accelerating the availability of life-saving treatments and addressing the current bottleneck in CGT manufacturing. This will benefit pharmaceutical companies developing these therapies and, ultimately, the patients who need them.
This transatlantic partnership leverages CGT Global’s experience in scaling during the COVID-19 pandemic, providing testing services to a wide range of organizations and expanding their infrastructure. Cellex brings its established European presence and experience in CAR-T manufacturing, serving a significant portion of the commercial CAR-T market in Europe. By combining their resources and expertise, they aim to streamline the entire CGT process, from cell collection to manufacturing and distribution, ultimately leading to more cost-effective treatments.
This collaboration represents a significant step toward a more integrated and efficient global CGT market. It could lead to faster commercialization of new therapies, wider patient access, and potentially lower treatment costs. The strengthened transatlantic connection between the two companies may also foster further innovation and collaboration within the CGT field, ultimately accelerating the development and delivery of these potentially life-saving treatments to patients worldwide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
